Cardiovascular regulation by the sympathetic nervous system is mediated by activation of one or more of the nine known subtypes of the adrenergic receptor family; α 1A -, α 1B -, α 1D -, α 2A -, α 2B -, α 2C -, β 1 -, β 2 -and β 3 -ARs (adrenoceptors). The role of the α 2 -AR family has long been known to include presynaptic inhibition of neurotransmitter release, diminished sympathetic efferent traffic, vasodilation and vasoconstriction. This complex response is mediated by one of three subtypes which all uniquely affect blood pressure and blood flow. All three subtypes are present in the brain, kidney, heart and vasculature. However, each differentially influences blood pressure and sympathetic transmission. Activation of α 2A -ARs in cardiovascular control centres of the brain lowers blood pressure and decreases plasma noradrenaline (norepinephrine), activation of peripheral α 2B -ARs causes sodium retention and vasoconstriction, whereas activation of peripheral α 2C -ARs causes cold-induced vasoconstriction. In addition, non-selective agonists elicit endothelium-dependent vasodilation and presynaptic inhibition of noradrenaline release. The evidence that each of these receptor subtypes uniquely participates in cardiovascular control is discussed in this review.
INTRODUCTION
The endogenous catecholamines adrenaline (epinephrine) and NE [noradrenaline (norepinephrine)] mediate sympathetic regulation of BP (blood pressure). These effectors of the sympathetic nervous system are synthesized within sympathetic neurons and chromaffin cells of the adrenal medulla by the well-defined series of reactions shown in Figure 1 . Adrenaline is the primary catecholamine product of chromaffin cells, whereas noradrenaline is produced in sympathetic neurons which lack PNMT (phenylethanolamine-N-methyl transferase). Both catecholamines act by binding to adrenergic receptors, or ARs (adrenoceptors), classified as α 1 -AR, α 2 -AR or β-AR. Each of these classes have multiple subtypes so that a total of nine subtypes have been characterized: α 1A , α 1B , α 1D , α 2A , α 2B , α 2C , β 1 , β 2 and β 3 . The subtypes were originally determined by agonist/ antagonist binding characteristics, but have more recently been characterized as separate gene products (reviewed in [1] ). Cardiovascular actions are mediated by central modulation of sympathetic efferent traffic, regulation of myocardial contractility to modulate cardiac output and direct effects on VSMC (vascular smooth muscle cells) and EC (endothelial cells) to control local blood flow and total vascular resistance. Blood vessels are innervated by sympathetic nerves that traverse in the adventitial layer and which have swellings or varicosities that release NE. NE acts on the underlying smooth muscle and endothelial cells to regulate vascular tone. Not every cell in the vascular wall is innervated and the spread of the signal is achieved by cell-to-cell junctions between adjacent smooth muscle cells [2] . Most small arteries and arterioles are innervated by noradrenergic axons, whereas capillaries and intramuscular venules are not (reviewed by Hill The rate-limiting enzyme in the pathway is tyrosine hydroxylase. Tyrosine hydroxylase requires O 2 , tetrahydrobiopterin and NADPH. It is regulated further by PKC (protein kinase C), PKA (protein kinase A), MAPKs (mitogen-activated protein kinases) and Ca 2+ /calmodulin kinases. In addition, caffeine, nicotine and opioids up-regulate the enzyme, whereas antidepressants down-regulate it. Gene transcription is regulated by CRE (cAMP-response element), AP-1, and NF-κB (nuclear factor κB). et al. [3] ). Although all three receptor subtypes contribute to BP control, this review will focus on the actions of the α 2 -AR subtypes.
CENTRAL α 2 -ARs
All three subtypes of the α 2 -AR are expressed within the central nervous system. Administration of α 2 -AR agonists into the cerebral ventricles causes a profound long-lasting fall in BP and increases plasma NE. These effects are accompanied by sedation, enhanced memory and increased attentional focus [4] [5] [6] . In cardiovascular control centres, the α 2A -AR is the most abundant subtype [7] . Furthermore, studies in mice with genetic mutations have shown that these central effects are primarily elicited by activation of the α 2A subtype [8, 9] . However, activation of both α 2B -and α 2C -ARs also elicit central effects. Mice with targeted inactivation of the α 2B -AR are resistant to the development of salt-sensitive hypertension [10, 11] and α 2B -AR antisense lowers BP in hypertensive rats [12, 13] . Mice deficient in α 2C -AR have an augmented startle response and sensorimotor gating deficits, whereas overexpression of the α 2C -AR increases the latency to the startle reflex and improves learning and memory [14, 15] . Thus all three receptors mediate central effects, with both α 2A -and α 2B -ARs contributing to BP regulation. However, the effects on BP can be opposite, since activation of central α 2A -ARs decreases BP by lowering sympathetic activity and activation of central α 2B -ARs appears to contribute to the development of salt-mediated sympathetic increases in BP (reviewed in [16] ).
The numerous effects elicited by central α 2 -AR stimulation have made it difficult to develop specific α 2 -AR agonists that lower BP or improve memory without the side effect of sedation. However, a recent study in heterozygous α 2A -AR-null mice [17] demonstrated that partial agonists may discriminately lower BP without causing drowsiness. In this study by Tan et al. [17] , mice heterozygously null for the α 2A -AR had a hypotensive response to central α 2 -AR agonists without the sedative effect, whereas homozygous-null mice did not develop either response and wild-type mice developed both. The authors suggest that partial α 2A -AR agonists may thus selectively elicit hypotension without the sedation, since only 50 % of the receptors are necessary for the hypotensive response, whereas greater than 50 % are required to achieve sedation. Thus, even within a single subtype of receptor, there appears to be a great heterogeneity in the downstream signalling responses.
Unlike the obvious sympatho-inhibition of the central α 2A -AR, the effects of central α 2B -AR activation are somewhat unclear. Initial studies with α 2B -AR-null mice demonstrated that these mice had an exaggerated hypotensive response to intravenous clonidine [18] , whereas α 2A -AR-null mice had only an initial pressor response [8] . In addition, α 2A -AR-null mice have increased NE concentrations in the heart [8] , augmented pressor responses to intravenous α 2 -AR agonists [19] and diminished autoinhibition of NE release [9] . However, ablation of the α 2A -AR did not eliminate presynaptic inhibition completely so that either α 2C -or α 2B -ARs appear to play some role [9] . Intriguing clinical data suggest that there is an increased risk of hypertension [20] , vascular disease [21] and augmented autonomic nervous system activity [22] in subjects carrying a functional deletion polymorphism in the α 2B -AR gene. In addition, this polymorphism is associated with increased risk for sudden cardiac death, suggesting this receptor may play an important role in mediating autonomic control of the cardiovascular system in humans [23, 24] .
The role of the α 2C -AR in mediating central control of BP and cardiac function is also still not totally [9] . However, combined null mutations in the α 2A -and α 2C -ARs leads to profound cardiac hypertrophy, elevated plasma NE and diminished left ventricular contractility, such as that seen in chronic sympathetic overload [9] . Thus it appears that the α 2C -AR compensates in part for loss of the α 2A -AR [25] . The different roles of the three different subtypes demonstrates the need to understand the efficacy of anaesthetic and antihypertensive drugs for the different subtypes. In addition, developing specific subtype selective agonists and partial agonists should improve the clinical usefulness of α 2 -AR ligands.
PHYSIOLOGICAL ACTIONS IN THE PERIPHERAL CIRCULATION
In addition to effects on sympathetic efferent traffic, cardiovascular function is also regulated by peripheral presynaptic and postsynaptic α 2 -ARs. VSMC and EC express multiple α 2 -AR subtypes (Table 1) , and the specific vascular responses regulated by each of the AR subtypes are discussed below. Activation of α 2A -, α 2B -and α 2C -ARs on VSMC causes contraction with resultant vasoconstriction. However, the distribution of the individual subtypes varies between vascular beds, between species and between large and small vessels. Thus α 2A -ARs appear to be expressed exclusively, or at least at a much higher concentration, in large arteries [26, 27] , whereas α 2B -ARs contribute more to vascular tone in small arteries and veins [28, 29] . In addition, there are multiple reports of α 2A -AR expression in cultured VSMC [27, [30] [31] [32] and of α 2A -AR constriction in isolated arteries [30, [33] [34] [35] . In dog mesenteric and rat femoral arteries, Paiva et al. [36] observed only α 2A -ARmediated constriction. In porcine nasal mucosal microvessels, Corboz et al. [37] observed α 2A -and α 2C -ARs but not α 2B -AR vasoconstriction. Villalon et al. [38] reported a similar distribution of α 2 -AR subtypes in the dog external carotid artery. Thus α 2A -ARs appear to contribute to control of tone in the carotid, mesenteric and mucosal vascular beds.
In other vascular preparations, α 2C -AR constriction predominates, especially in cold-induced vasoconstriction. Functional studies in the rat tail artery suggest that at 37
• C α 2C -ARs do not contribute to α 2 -AR vasoconstriction. However, the α 2C -AR is the dominant AR mediating vasoconstriction at 28
• C [39, 40] . Environmental factors thus regulate the functional coupling of α 2C -ARs to intracellular effector pathways. For example, recent studies in dermal and aortic VSMC demonstrate that small arteries express more functional α 2 -ARs than large vessels and that α 2C -ARs specifically are up-regulated by exposure to serum [41] . In HEK-293 cells transfected with human α 2C -ARs, activation of α 2C -ARs was only observed during cold. In those studies, exposure to cold increased coupling of α 2C -ARs to adenylate cyclase, but did not affect α 2A -AR coupling [42] . Thus temperature appears to regulate cellular distribution and second messenger coupling of α 2C -AR. Clinical studies in Raynaud's patients have also documented a significant role for α 2 -ARs in the exaggerated cold-induced vasoconstriction typical of this syndrome [40, 43, 44] , although there are other reports that α 2 -AR blockade has little or no effect on cold-induced vasoconstriction [45] [46] [47] . In addition, the α 2C -ARs appear to contribute to cerebral blood flow by regulating tone in the carotid artery [48, 49] , and recent studies suggest subtype selective activation of these receptors causes vasoconstriction which may be a beneficial therapy for migraine [38, 49] . Thus α 2C -ARs may play a unique and very selective role in thermoregulation.
In vivo studies in conscious mice suggest that vascular α 2B -ARs contribute more to BP regulation than do vascular α 2A -or α 2C -ARs. For example, clonidine administered intravenously to α 2B -AR-null mice did not elicit a pressor response, but did lead to an exaggerated depressor response [18] . In contrast, clonidine administered to α 2A -AR-null mice caused an exaggerated pressor response without the secondary depressor response [8] . In contrast, α 2C -AR-null mice responded similarly to wild-type mice with both a pressor and depressor response [18] . Thus it appears that α 2B -ARs on small arteries play a greater role in regulating total peripheral vascular tone than do either α 2A -or α 2C -ARs. This is somewhat confusing based on the expression and constrictor studies in isolated arteries. However, endogenous circulating factors profoundly affect α 2 -AR coupling so that in vivo responses may be very different from observations in vitro [50] [51] [52] .
One conflicting report suggested that vasoconstriction is primarily mediated by α 2A -ARs. In this study [53] , heterozygous α 2B -AR-null mice retained a pressor response to intravenous NE in the presence of prazosin, whereas homozygous α 2A -AR-null mice did not. Thus the authors [53] concluded that α 2A -ARs may be the most important subtype in mediating vasoconstriction to NE. However, α 2B -and α 2C -ARs are blocked by prazosin [54, 55] so that, in the presence of prazosin, α 2B -ARs would be pharmacologically inactivated. Therefore these studies do suggest that α 2A -ARs contribute to vasoconstriction, but do not eliminate a role for vascular α 2B/C -ARs.
Overall, it appears that multiple α 2 -ARs can cause vasoconstriction in most vascular beds, but the specific subtypes mediating smooth muscle constriction differ. Development of subtype selective agonists and antagonists will help to elucidate potential pathological effects of perturbations to this system.
In addition to studies in animal models of hypertension, genetic linkage studies suggest vascular α 2B -ARs may contribute to some forms of hypertension and vascular disease in the human population. Recent studies have identified a functional deletion polymorphism in the α 2B -AR gene on chromosome 2 that associates with the development of hypertension [20] . This is corroborated by a genome-wide meta-analysis which found significant or highly suggestive linkages to hypertension and diastolic BP linkage on chromosome 2 at the region of the α 2B -AR gene (p12-q22.1) [56] . This is supported further by individual studies reporting a significant linkage to hypertension in the same region on chromosome 2 in a Chinese hypertensive population [57] and in a general Scandinavian population [56] . Other linkage studies suggest that expression of the short form of the α 2B -AR (SS or DD) is significantly linked to altered autonomic nervous system function [22] , increased risk of sudden cardiac death [24] and diminished brachial artery dilation [21] . Thus altered function of the α 2B -AR may contribute to vascular pathology in the human condition.
Recent studies in α 2B -AR-null mice suggest that loss of this receptor decreases the development of salt-induced hypertension [10] and that central administration of α 2B -AR antisense lowers BP, as discussed above [12, 13] . However, these effects may be very specific to central α 2B -ARs and not mediated by vascular and renal receptors. Observations from our laboratory in these same mice suggest that they are more susceptible to hypertension caused by NOS (nitric oxide synthase) inhibition [57a] . Thus the increased susceptibility to hypertension in patients with the short form of the α 2B -AR gene may represent a decrease in function that augments vascular dysfunction.
Another potential site of action of α 2 -ARs in the periphery is on vascular EC. Activation of endothelial α 2 -ARs increases production of nitric oxide and other Ca 2+ -driven vasodilators [58, 59] . This vasodilation has been demonstrated in both isolated arteries [60] [61] [62] [63] and in whole animal studies [64] [65] [66] . However, the specific receptor subtype(s) mediating this dilation is not defined. In isolated rat mesenteric arteries, a portion of the antihypertensive response to clonidine is dependent on endothelial-dependent dilation [67] . In addition, treatment with NOS or COX (cyclo-oxygenase) inhibitors is required to uncover α 2 -AR constriction of endothelium intact arteries [68] , suggesting that α 2 -ARs in intact arteries have a predominantly dilatory effect. However, in arteries from hypertensive rats [69, 70] or humans [16, 71] , there is an increased α 2 -AR-mediated constriction. Thus loss of endothelial dilation may increase postsynaptic α 2 -AR constriction, as suggested by animal models of eNOS (endothelial NOS) inhibition [68, 69] .
CLINICAL IMPLICATIONS
Because of the many divergent effects of the α 2 -AR subtypes, it is apparent that mixed agonists and antagonists will have multiple effects. This is particularly important when dealing with drugs that have been incorrectly labelled as 'selective', such as the common antagonist prazosin. Since this antagonist has efficacy at both α 1 -and α 2B/C -ARs [55] , effects of prazosin cannot be attributable solely to inhibition of α 1 -ARs. The additional α 2B -AR blockade may in fact improve the antihypertensive efficacy by decreasing BP sensitivity to salt [11] . Thus blockers that inhibit both α 1 -and α 2B -ARs but not α 2A -AR should be more effective as antihypertensive agents than pure α 1 -AR blockers. With α 2 -AR agonists such as α-methyl-dopa or clonidine, α 2A -AR-selective agonists should be more effective than mixed agonists. That is, activation of the α 2A -ARs will inhibit sympathetic efflux and lower BP, whereas activation of the α 2B -ARs will increase sympathetic discharge and raise BP. Thus the non-selective activity of clonidine makes it a less appropriate treatment than a more selective agonist such as dexmedatomidine [72] . Finally, anaesthetics with α 2B -AR agonist activity, such as etomidate [29] , should help to stabilize BP by causing vasoconstriction.
In summary, recent studies suggest that α 2 -AR vasoconstriction may contribute to the development of hypertension, migraines and Raynaud's syndrome (Figure 2 ). In addition, genetic linkage studies suggest that altered expression/function of the α 2B -AR is specifically linked to multiple vascular diseases. Conversely, central α 2B -ARs appear to participate in the development of saltsensitive forms of hypertension, whereas central α 2A -ARs limit sympathetic efferent traffic. Thus the α 2 -AR family of ARs participates in the regulation of the cardiovascular In the vasculature, both α 2A -and α 2B -ARs elicit vasoconstriction with a predominant effect of α 2B -ARs in veins [53, 73] . Endothelium-mediated dilation is elicited by undefined α 2 -AR subtype(s). In the central nervous system (CNS), all three subtypes are expressed and elicit unique responses. Inhibition of sympathetic efflux is elicited primarily by α 2A -ARs, although α 2C -ARs also participate in this response [9] . Hypothalamic α 2B -ARs appear to mediate sympathetic activation in response to salt loading [11] . In the heart, presynaptic α 2A -and α 2C -ARs regulate growth, so that a double null-mutation results in cardiac hypertrophy [74] . EDRF, endothelium-derived releasing factor; SNSA, sympathetic nervous system activity; MCFP, mean circulatory filling pressure.
system at many levels. The lack of clinically available subtype-selective compounds, however, limits the ability of α 2 -AR modulators to be used to elicit a selective beneficial effect. Thus the development of either genetic manipulation (silencing RNA) or more selective agonists and antagonists for the α 2 -ARs has the potential to greatly impact on therapeutics for hypertension and vascular disease.
